BRG
VRTX icon

Bay Rivers Group’s Vertex Pharmaceuticals VRTX Stock Holding History

Bay Rivers Group’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.04M Buy
2,100
+100
+5% +$44.3K 0.36% 47
2026
Q1 		$893K Buy
+2,000
New +$933K 0.37% 47

Other funds holding VRTX

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
WF
Welch & Forbes Boston, Massachusetts $8.23B AUM 17.62% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

Bay Rivers Group's VRTX Position: Q2 2026 in Review

Bay Rivers Group increased its Vertex Pharmaceuticals (VRTX) stake by 5% in Q2 2026, buying an estimated $44.3K and bringing the position to 2,100 shares worth $1.04M. The position accounts for 0.36% of the portfolio, ranked #47.

Bay Rivers Group first reported a position in VRTX in Q1 2026 and has held it in 2 quarters since. 708 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Bay Rivers Group held 2,100 shares of Vertex Pharmaceuticals worth $1.04M as of Q2 2026.
  • Bay Rivers Group bought 100 Vertex Pharmaceuticals shares in Q2 2026, an estimated $44.3K.
  • Vertex Pharmaceuticals made up 0.36% of Bay Rivers Group's portfolio in Q2 2026, its #47 holding.
  • Bay Rivers Group first reported a position in Vertex Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 708 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Bay Rivers Group's 13F filing for Q2 2026, filed 9 Jul 2026.